Jefferies Financial Group Initiates Coverage on Alvotech (NASDAQ:ALVO)

Jefferies Financial Group initiated coverage on shares of Alvotech (NASDAQ:ALVO – Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $9.00 price target on the stock. Jefferies Financial Group‘s price objective suggests a potential upside of 82.93% from the stock’s previous close.

A number of other equities analysts have also issued reports on ALVO. Wall Street Zen lowered Alvotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Barclays upgraded Alvotech from an “underweight” rating to an “overweight” rating and lifted their price target for the company from $4.00 to $8.00 in a research report on Wednesday, September 16th. Bank of America began coverage on Alvotech in a research note on Monday, August 24th. They issued a “buy” rating and a $7.00 price objective on the stock. Zacks Research lowered Alvotech from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Finally, UBS Group set a $8.00 price objective on Alvotech in a report on Wednesday, September 16th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Alvotech presently has an average rating of “Hold” and an average price target of $8.40.

Check Out Our Latest Stock Analysis on ALVO

Alvotech Stock Performance

ALVO stock opened at $4.92 on Tuesday. The firm’s 50-day moving average is $5.27 and its two-hundred day moving average is $4.21. Alvotech has a 52 week low of $2.94 and a 52 week high of $6.53.

Alvotech (NASDAQ:ALVO – Get Free Report) last posted its quarterly earnings data on Wednesday, November 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. The company had revenue of $111.60 million during the quarter, compared to the consensus estimate of $125.20 million. Equities analysts anticipate that Alvotech will post -0.01 earnings per share for the current fiscal year.

Institutional Trading of Alvotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in Alvotech in the second quarter worth approximately $6,376,000. Royce & Associates LP acquired a new stake in shares of Alvotech during the 3rd quarter valued at $3,817,000. Renaissance Technologies LLC lifted its position in shares of Alvotech by 146.9% during the 1st quarter. Renaissance Technologies LLC now owns 63,200 shares of the company’s stock valued at $217,000 after acquiring an additional 37,600 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Alvotech during the 3rd quarter valued at $100,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Alvotech by 24.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 61,712 shares of the company’s stock worth $365,000 after acquiring an additional 12,049 shares in the last quarter.

Alvotech News Roundup

These are some of the ALVO news items that stood out recently:

  • Positive Sentiment: The FDA accepted Alvotech’s application for its proposed Entyvio biosimilar, while the company and partner Advanz submitted a proposed Eylea HD biosimilar application in Europe. FDA-approved production changes for Simlandi are expected to more than double output per batch and add manufacturing flexibility. Business update
  • Negative Sentiment: Third-quarter revenue was $111.6 million, below the cited analyst estimate of $125.2 million. Alvotech also reported a quarterly loss that missed consensus, although published per-share figures differ across reports. Quarterly earnings report
  • Negative Sentiment: Nine-month adjusted revenue fell 23% year over year to $323.4 million, gross margin narrowed to 54% from 59%, and cash declined to $61.5 million from $172.4 million at year-end 2025. The company maintained its 2026 revenue and EBITDA ranges but now expects results toward the lower end. Alvotech Q3 revenue falls

About Alvotech

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

See Also

Analyst Recommendations for Alvotech (NASDAQ:ALVO)

Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.